@article{074bd151de4d4f988c0f473b43ba49ae,
title = "Checkpoint inhibitor-induced myocarditis and myasthenia gravis in a recurrent/metastatic thymic carcinoma patient: a case report.",
author = "Charles Szuchan and Leah Elson and Evan Alley and Kevin Leung and Camargo, \{Antonio Lewis\} and Elizabeth Elimimian and Zeina Nahleh and Diego Sadler",
note = "Pembrolizumab, an immune checkpoint inhibitor (ICI), is an IgG4 antibody that blocks interaction between programmed cell death protein 1 and programmed death-ligand 1. Myocarditis, an immune-related adverse event, has been reported in thymic epithelial tumours. Pembrolizumab has also been associated with development/exacerbation of myasthenia gravis (MG).",
year = "2020",
month = jun,
day = "1",
doi = "10.1093/EHJCR/YTAA051",
language = "American English",
volume = "4",
journal = "European Heart Journal - Case Reports",
number = "3",
}